Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI Singapore ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while iShares MSCI Singapore ETF trades at $30.99. The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | EWS | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $30.66 |
52-Week Low | $10.24 | $26.08 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EWS, the iShares MSCI Singapore ETF, trades at $30.28, up 0.4% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF offers a 3.97% dividend yield and is approaching its 2007 all-time high of $31.94, supported by Singapore's economic stability and financial sector strength. Recent news highlights focus on Singapore's AI initiatives and property market activity.
The outlook for EWS is positive, with potential upside to the $31.94 resistance level, but risks include concentrated holdings in financials and regional economic sensitivity. Investor sentiment is mixed, with some analysts advocating for diversification benefits while others caution on valuation after recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
